DOACs and reversal agents for patients experiencing ICH: Latest evidence - touchNEUROLOGY

touchEXPERT OPINIONS for touchNEUROLOGY

Leading experts share their insights on the impact of intracerebral haemorrhage (ICH) in patients receiving direct oral anticoagulants (DOACs), DOAC-ICH reversal agents and optimizing treatment outcomes.

The experts:

• Prof. Hanne Christensen, University of Copenhagen, Denmark
• Prof. Thorsten Steiner, The Clinical Centre in Frankfurt Höchst, Frankfurt, Germany
• Dr Truman Milling, The University of Texas at Austin, TX, USA

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit:
www.touchneurology.com